Brieflands

History

The company was first founded by Seyyed M. Miri and Seyed-M Alavian as an editorial group in a Medical Institute in 2007 to publish its medical journal. After three years of experience, the number of journals increased to 5 journals, and the company launched its first form of business as a VOF (collaboration) professional STM company in Heerlen, the Netherlands, which was called "Kowsarmedical Publishing." Respecting the publishing services (from submission to publishing), especially an in-house "Journal Management System," our journals increased to more than 60 STM journals between 2010 and 2019. Since 2022, "Brieflands" is the new brand name that acts as a "Science, Technical, Medical Publisher" that publishes more than 50 journals with the services provided by 97 expert employees in three different branches.

Business Profile

  • Brieflands is a Registered Trademark with record number 1454012.
  • Brieflands has been registered as a General partnership (Vennootschap onder firma) company in the Chamber of Commerce (Kamer van Koophandel) of the Netherlands since 2010.
  • Nedmedica is our related company which is specialized in Author Services. 
  • Our former branding name was Kowsarmedical Publishing (2010-2021).
 

Communities in Brieflands

Select a community to browse its collections.

Recent Submissions

Thumbnail Image
Item
Multimodal Regional Anesthesia Combining Spinal and Erector Spinae Plane Block for Spine Surgery in a High-Risk Patient with Systemic Sclerosis: A Case Report
(Brieflands, 2025-04-30) Alireza Shakeri; Jina Behjati; Alireza Shakeri [0000-0001-8095-7168]
Introduction: The erector spinae plane block (ESPB) is a novel regional anesthesia technique that is increasingly incorporated into multimodal analgesia as part of enhanced recovery after surgery (ERAS) pathways in various surgical procedures, including spine surgery. Case Presentation: We report the successful use of spinal anesthesia (SA), ESPB, and magnesium sulfate in a high-risk patient with systemic sclerosis and pulmonary fibrosis undergoing laminectomy. A multimodal approach was selected due to the patient’s underlying condition. This strategy minimized respiratory complications associated with general anesthesia while providing effective surgical anesthesia and postoperative pain control without opioid-related complications. Conclusions: Our case highlights the utility of ESPB, not only for postoperative pain management but also as a valuable adjunct to primary anesthesia, especially in high-risk patients.
Thumbnail Image
Item
The Effects of Vitamin D Supplementation on Vertigo and Tinnitus in Patients with Meniere’s Disease: A Randomized Clinical Trial
(Brieflands, 2025-12-31) Ali Talebi; Nasrin Yazdani; Amir Kasaeian; Sepide Talebi; Niayesh Mohebbi; Niayesh Mohebbi [0000-0002-1420-7286]
Background: The present study aimed to evaluate the impact of vitamin D supplementation as an adjuvant therapy on tinnitus and vertigo in individuals diagnosed with Meniere’s disease. Methods: The study was conducted from November 2021 to October 2022 at Tehran University Hospital, Tehran, Iran. This clinical trial involved 60 individuals diagnosed with Meniere’s disease and vitamin D deficiency. Participants were randomly allocated to receive either vitamin D (50,000 IU weekly) or a placebo for eight weeks. The study assessed the frequency, intensity, and duration of vertigo attacks, as well as several measures of dizziness and tinnitus, both before and after the intervention. Results: No significant change was observed in the number of vertigo attacks (P = 0.85), the duration (P = 0.52), or the severity of vertigo (P = 0.33) in the vitamin D group compared to the placebo group at the end of the trial. Additionally, vitamin D supplementation did not significantly affect the results of various dizziness and tinnitus indices at the study’s conclusion (P > 0.05). As expected, serum levels of vitamin D were significantly higher in the intervention group compared to the placebo group at the trial's endpoint (P < 0.001). Conclusions: Vitamin D supplementation did not significantly affect vertigo and tinnitus in patients with Meniere’s disease. Further clinical trials with larger sample sizes and longer durations are recommended to confirm these findings.
Thumbnail Image
Item
Acne Treatment Based on Cannabinoids: Efficacy and Legislation Perspectives
(Brieflands, 2025-03-31) Helena Pocay Araujo; Thais Giovanetti Esteves Santos; Flavia Sobreira Mendonca Goncalves; Priscila Alves Balista; Rodrigo Vieira Gonzaga; Michelli Ferrera Dario; Helena Pocay Araujo [0009-0007-5586-2563]; Thais Giovanetti Esteves Santos [0009-0001-8011-8396]; Flavia Sobreira Mendonca Goncalves [0009-0005-1383-4164]; Priscila Alves Balista [0000-0001-8670-4217]; Rodrigo Vieira Gonzaga [0000-0002-2815-1383]; Michelli Ferrera Dario [0000-0002-0050-4378]
Context: Acne is a prevalent inflammatory condition affecting individuals globally, particularly during adolescence, and has a significant psychosocial impact. Its pathogenesis involves sebaceous hypersecretion, follicular hyperkeratinization, and microbial dysbiosis, primarily associated with Cutibacterium acnes. Conventional acne treatments, including topical and systemic therapies, often cause adverse effects, highlighting the need for new, safer options. Cannabidiol (CBD), a non-psychoactive compound from Cannabis sativa, has emerged as a promising candidate due to its anti-inflammatory and antioxidant properties. This review discusses acne pathophysiology and examines CBD's therapeutic potential alongside global regulatory perspectives on its use in cosmetics. Evidence Acquisition: A literature search was conducted for articles on acne pathogenesis, endocannabinoid systems, and CBD's pharmacological effects. Results: Acne’s inflammatory nature is driven by androgen-induced sebum production, follicular hyperkeratinization, and microbial imbalance, mainly involving C. acnes. Androgens activate receptors in sebaceous glands, increasing sebum production and contributing to pore blockages and inflammatory responses. Although effective, conventional treatments such as retinoids and antibiotics often have undesirable side effects, driving interest in plant-based alternatives. The CBD shows potential as an acne treatment by modulating inflammation through CB2 receptor and TRPV1 channel activation, which directly helps reduce the inflammatory response that contributes to acne severity. It also reduces sebocyte proliferation, addressing the hyperkeratinization that leads to clogged pores, and inhibits cytokines like TNF-α, reducing the inflammatory processes that exacerbate acne lesions. The CBD also acts as an antioxidant, mitigating oxidative stress associated with acne-related inflammation. Furthermore, CBD’s lipophilic nature facilitates its accumulation in the stratum corneum, enabling prolonged skin interaction with minimal systemic absorption. A review of regulations reveals varying levels of acceptance for CBD in cosmetics, with North America and Europe allowing its use under specific guidelines, while restrictions remain stricter in other regions. Conclusions: The CBD represents a multi-targeted, safer alternative for acne management, addressing key mechanisms of acne pathogenesis, such as inflammation, sebocyte activity, and oxidative stress, without the adverse effects of conventional treatments. Further studies are necessary to validate these findings in clinical settings and establish standardized guidelines for the safe inclusion of CBD in skincare products.
Thumbnail Image
Item
Relationships Between Preterm Premature Rupture of Membrane at Gestational Age 20 - 36+6 Weeks and Perinatal Outcomes; A Cross-Sectional Study from Tehran, Iran
(Brieflands, 2025-07-31) Zahra Panahi; Wajid Abbas; Fahimeh Ghotbizadeh Vahdani; Mamak Shariat; Fahimeh Ghotbizadeh Vahdani [0000-0002-2653-8429]; Mamak Shariat [0000-0002-7547-8004]
Background: Preterm premature rupture of membranes (PPROM) significantly contributes to fetal and maternal complications. Objectives: This study aimed to evaluate the risk factors, comorbidities, and outcomes associated with PPROM based on a well-characterized retrospective study. Methods: A cross-sectional study was conducted in Tehran, Iran, from 2020 to 2023. Patient files were assessed, and relevant data were extracted, including patients' age, underlying diseases, gestational age at admission, events preceding or following PROM, cause of death, cervical length, and duration of hospital admission. All data were statistically analyzed to identify correlations between PPROM and various variables. Results: A total of 396 patients with PPROM were included, and 153 separate neonatal files were reviewed. The mean gestational age at admission was 31.1 weeks. The main comorbidities associated with PPROM were vaginal bleeding (39.2%), labor pain (20.2%), and chorioamnionitis (10.7%). The mean duration of maternal hospitalization was 4 days. Low gestational age was a significant risk factor for neonatal mortality (P = 0.002), respiratory distress syndrome (RDS) (P < 0.001), and surfactant requirement (P = 0.008). Neonates with lower birth weights were at higher risk for surfactant requirement (P = 0.025). Normal vaginal delivery (NVD) was a significant factor influencing neonatal mortality among PPROM patients (P = 0.0001). The need for surfactant administration was more frequently observed in neonates born by cesarean delivery (P = 0.047). Conclusions: The findings of this study indicate that vaginal bleeding is a major complication following PPROM. Preterm premature rupture of membranes also leads to increased perinatal mortality and morbidity. These findings underscore the importance of early diagnosis and interventions to prevent adverse outcomes.
Thumbnail Image
Item
Strategic Purchasing Solutions in Line with Sustainable Financing of the Health System: A Scoping Review
(Brieflands, 2025-05-31) Mohsen Barouni; Anahita Behzadi; Amirhossien Fatahpour; Mohsen Barouni [0000-0001-6955-0818]; Anahita Behzadi [0000-0002-6988-3759]; Amirhossien Fatahpour [0000-0002-8199-5462]
Context: Health financing involves the collection and management of resources necessary for delivering health services. Sustainable financing is crucial for achieving universal health coverage (UHC). By improving access to services and implementing strategic purchasing practices, resources can be used more efficiently, thereby enhancing the quality of care. This study explores strategic purchasing solutions that support sustainable financing for health systems. Evidence Acquisition: In 2024, we conducted a scoping review adhering to PRISMA guidelines to ensure a comprehensive and systematic approach. We developed an extensive search strategy to identify studies related to strategic purchasing solutions that support the sustainable financing of health systems. Our search encompassed the PubMed, Web of Science, Embase, Google Scholar, Scopus, and ProQuest databases, using relevant keywords from December 21, 2002, to December 21, 2024. Ultimately, we analyzed 84 identified records using MAXQDA software and the Arksey and O’Malley framework for analysis. Results: The strategic purchasing solutions identified were categorized into 39 distinct solutions across five main categories. These categories include: Service provider solutions (5), purchaser solutions (6), payment method solutions (14), package solutions (5) and stewardship solutions (9). Among these, the payment method category featured the highest number of repetitions, with performance-based payment being the most frequently mentioned approach. Conclusions: To achieve sustainable health financing through the strategic purchasing of health services, the following approaches should be adopted: Encourage private sector involvement in underserved, low-income regions; foster trust and ensure quality by enhancing credibility and incorporating community feedback; establish negotiated rates with insurers using regulated tariffs and value-based pricing to improve service quality and minimize disputes; introduce a universal basic insurance package to guarantee fair access for all; and prioritize preventive care to reduce long-term healthcare expenses. Moreover, health technology assessment (HTA) should be tailored to address the specific needs of vulnerable populations.